Ipsen Partners with Dassault Systemes to Develop Advanced Programs using the 3DEXPERIENCE Platform

By CIOReview | Thursday, April 14, 2016
738
1229
247

developing advanced and creative programs using the 3DEXPERIENCE platformFREMONT, CA: Dassault Systèmes, a software company that develops 3D design, 3D digital mock-up, and product lifecycle management solutions and Ipsen, a global specialty-driven pharmaceutical group recently announced entering into a partnership for developing advanced and creative programs using the 3DEXPERIENCE platform.

By selecting the “Designed to Cure” industry solution experience from Dassault Systèmes, Ipsen looks to speed up and simplify its research and development (R&D) transformation and discovery of new therapeutic solutions. The Designed to Cure platform offers data integration, collaboration, knowledge driven innovation and predictive analytics, which will provide Ipsen high quality and accessible scientific knowledge across the organization. The platform strengthens decision-making through real-time views across the lifecycle of therapeutics innovation.

Furthermore, the platform will provide modeling and simulation capabilities to capture a complete view of the dysregulations associated to diseases as well as improve and shorten the identification of higher quality drug candidates. The Designed to Cure platform also accelerates drug design and development by combining in silico and physical experiments, while integrating Quality-by-Design principles to comply with regulations.

Simulation has also long been recognized for the integral role it plays in high-risk industries. In the healthcare industry it is the significant factor to cost-effective and competitive management of healthcare operations. In essence, this collaboration is focused on optimizing the R&D processes of Ipsen’s multi-disciplinary teams located in the core of the leading biotechnological and life sciences hubs worldwide.

“After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools,” said Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, Ipsen. “Ipsen as a key scientific partner has ‘open innovation’ in its DNA and this new collaborative and innovative digital platform will support Ipsen’s commitment to achieve therapeutic breakthroughs in patient care.”

“The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before,” said Jean Colombel, Vice President, Life Sciences Industry, Dassault Systèmes. “Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences.”